Jay Garg - Concepedia

Author

Jay Garg

University of California, San Francisco

Also Known As

Garg, Jhanvi, J GARG, J Garg, J. Garg, J. P. Garg, J.P. Garg, Jay Garg, Jay P Garg, Jay P. Garg, Joshua Garg

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco Roche (Switzerland)NOAA National Centers for Environmental Information Jet Propulsion Laboratory Scripps Institution of Oceanography

About

Jay Garg is an author at University of California, San Francisco specializing in medicine, lupus, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	268
2	Immunology	2	2	177
3	Public Health	1	1	81
4	Clinical Immunology	1	1	12
5	Economics	1	1	81

Jay Garg

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study Brad H. Rovin, Richard Furie, Kevin Latinis, Arthritis & Rheumatism	2012	1.4K
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial Richard Furie, Gustavo Aroca, Matthew D. Cascino, Annals of the Rheumatic Diseases	2022	392
Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts Jay Garg, W ELLIOTT, Amy Folker, American Journal of Hypertension	2005	256
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, Clinical Journal of the American Society of Nephrology	2018	174
A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation Flavio Vincenti, R. Méndez, Mark D. Pescovitz, American Journal of Transplantation UrologyTransplantationKidney TransplantKidney TransplantationTransplantation Medicine	2007	165
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis Richard Furie, Brad H. Rovin, Jay Garg, New England Journal of Medicine	2025	122
Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial Jay Garg, Scott Chasan‐Taber, Andrew T. Blair, Arthritis & Rheumatism	2005	113
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate Alan Kivitz, Sergio Gutiérrez‐Ureña, Jeffrey E. Poiley, Arthritis & Rheumatology	2016	107
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis Mark C. Genovese, Maria Greenwald, Christine E. Codding, Arthritis & Rheumatology	2017	89
Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database Elise M. Pelletier, Sarika Ogale, Elaine Yu, Clinical Therapeutics EconomicsHealthcare ValueEconomic OutcomesHealth EconomicsSystemic Lupus Erythematosus	2009	81

Page 1